Santagata Davide: How Biological Sex Influences Thrombotic Risk in Patients with Cancer?
Santagata Davide, Resident in Internal Medicine at University of Insubria, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“New publication
Yesterday we marked International Women’s Day — but research in gender medicine should not be limited to a single day.
Our new review explores sex differences in cancer-associated thrombosis, highlighting how biological sex influences thrombotic risk, clinical presentation, and treatment outcomes in patients with cancer.
Importantly, we also propose a research agenda calling for sex-stratified analyses and better integration of biological and real-world data to improve risk prediction and advance personalized care in oncology and thrombosis.
Grateful for being part of this publication.
Huge thanks to all the authors and Prof. Roberta Gualtierotti for this collaboration.”
Title: Sex Differences in Cancer-Associated Thrombosis
Authors: Andrea Giachi, Davide Santagata, Addolorata Truma, Andrea Artoni, Paolo Bucciarelli, Luca Valenti, Cihan Ay, Roberta Gualtierotti
Read the Full Article on International Journal of Molecular Sciences

Stay updated on all scientific advances with Hemostasis Today.
-
Jun 15, 2026, 13:13Christina Ornauer: Exploring the Latest Advances in Hematology at EHA 2026
-
Jun 15, 2026, 13:05Angelo Zanniti: Back from EHA 2026 Congress
-
Jun 15, 2026, 12:56Chiara Pirillo: Building Global Connections at EHA 2026
-
Jun 15, 2026, 12:50Marina Planas: MRD and Molecular Monitoring Take Center Stage at EHA 2026
-
Jun 15, 2026, 12:46Moonmoon Kazi: Climb Bio Presents Phase 1b ITP Trial Data at EHA 2026
-
Jun 15, 2026, 12:44Wolfgang Miesbach: Base Editing and the Future of Sickle Cell Disease Therapy
-
Jun 15, 2026, 12:31Chandrashekhar Athare: EHA 2026 Concludes with Lasting Impact and New Collaborations
-
Jun 15, 2026, 10:49Aurelio Maggio: How Is The Treatment Landscape Of Thrombotic Thrombocytopenic Purpura Evolving?
-
Jun 15, 2026, 10:49Marek Mráz: A Landmark EHA 2026 for Our Lab